Insmed Announces Top-line Results from Phase 1 Trial of TPIP

Insmed Announces Top-line Results from Phase 1 Trial of TPIP

287718

Insmed Announces Top-line Results from Phase 1 Trial of TPIP

Top-line data from a Phase 1 clinical trial has found that treprostinil palmitil inhalation powder (TPIP) — a dry powder form of a treprostinil precursor that is being developed by Insmed for treating pulmonary arterial hypertension (PAH) — was safe and well-tolerated in healthy volunteers. Results also showed that TPIP had a favorable pharmacological profile that allows for the medication to be given once daily. TPIP achieved lower maximum concentrations in the blood of healthy volunteers…

You must be logged in to read/download the full post.